A December 12 physician event in Buenos Aires will introduce a new aesthetic cellular technology initiative within Cellgenic’s expanding regenerative medicine portfolio.
MIAMI, FL — November 6, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced that its advanced biologics division, Cellgenic, is preparing to introduce an autologous fibroblast product developed through its laboratory operations in Buenos Aires, Argentina.
The initiative expands Cellgenic’s work in cellular technologies for aesthetic medicine and complements its existing portfolio spanning regenerative biologics, stem cell technologies, exosomes and peptides.
Autologous fibroblast technology involves cells derived from an individual’s own tissue and is an area of research and development for potential aesthetic and tissue applications. Any clinical commercialization or use will depend on the applicable regulatory authorizations, medical requirements and product-specific evidence.
Cellgenic plans to formally present the technology at a physician networking and product introduction event in Buenos Aires on December 12, 2026, bringing together medical professionals, industry leaders and commercial partners.
“Argentina is becoming one of the most important markets in our international expansion strategy,” said Dave Christensen, CEO and President of Regenerative Medical Technology Group. “With Cellgenic’s expanding laboratory and commercial presence, we are building a platform that extends beyond traditional biologics distribution. Autologous fibroblast technology is an exciting addition to our aesthetic medicine pipeline, and our ambition is to establish Cellgenic as a leading force in the Argentine regenerative medicine market.”
The Company intends to support physician education, scientific collaboration and further product development in Argentina while continuing to expand its commercial infrastructure.
“Our strategy combines laboratory capabilities, a strong commercial organization and continuous physician education,” Christensen added. “As we introduce additional technologies, we expect Argentina to become an increasingly important contributor to Cellgenic’s international growth.”
About the Operating Division
Cellgenic is the advanced biologics and regenerative medicine commercialization division of Global Stem Cells Group, focused on cellular technologies, regenerative products and physician engagement. www.cellgenic.com
About RMTG
Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com
Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.
Investor Relations
Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |
